Retatrutide, a triple agonist: early kidney signals

Evidence tier

Emerging / Investigational · Dual / triple agonist

Plain-language summary

Phase-2 post-hoc analyses showed reductions in urine albumin-to-creatinine ratio. TRANSCEND-CKD (renal function by iohexol mGFR) completed in October 2025, but no efficacy/mGFR results have been reported yet; the pivotal phase-3 TRIUMPH-Outcomes programme is not expected before 2028–2029. Investigational — no reported phase-3 kidney-outcome results yet.

Key findings

Phase-2 post-hoc: UACR reductions (~31–37% at 12 mg) and eGFR gains.
TRANSCEND-CKD (NCT05936151): phase-2b, mGFR; completed Oct 2025, results not yet published.
TRIUMPH-Outcomes (NCT06383390): phase-3 CV + kidney outcomes, ~2028–2029.

Population

Adults with obesity and/or type 2 diabetes, with CKD in the dedicated renal study.

What this does not prove

No reported phase-3 kidney-outcome results yet; retatrutide is investigational and not approved. Post-hoc signals are hypothesis-generating.

Primary source

TRANSCEND-CKD NCT05936151 — completed October 2025; no results posted yet.
https://clinicaltrials.gov/study/NCT05936151
TRIUMPH-Outcomes NCT06383390 — ongoing trial, no results published.
https://clinicaltrials.gov/study/NCT06383390

Educational only

Paraphrased from the primary publication; not individual medical advice. Verify against the source before applying to care.